TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00682487

Intervention type: OTHER
Intervention: Hair sampling for cortisol
Description: Hair sampling for cortisol

Intervention type: OTHER
Intervention: Hair sampling for cortisol
Description: Hair sampling for cortisol
Study: NCT00887003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: High Volume, Low Dose (10cc, 5mg plain Bupivacaine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: High Volume, High Dose (10cc, 10mg plain Bupivacaine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depo-Medrol
Description: 80mg Depo-Medrol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depo-Medrol
Description: 80mg Depo-Medrol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depo-Medrol
Description: 80mg Depo-Medrol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depo-Medrol
Description: 80mg Depo-Medrol
Study: NCT02557945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Subjects will be treated with 400mg pills of gabapentin , titrating up to 3600mg per day, or 9 tablets (3 tabs tid)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be treated with 400mg pills of placebo, titrating up to 3600mg per day, or 9 tablets (3 tabs tid)
Study: NCT01891591

Intervention type: PROCEDURE
Intervention: Roux-en-Y gastric bypass (RYGP)
Study: NCT03952832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02627014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: 6 treatments: 2 treatments for week~1 treatment = 30 minutes
Study: NCT04243317

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle & diet
Description: The control group will receive lifestyle and dietary advice accompanied by meal replacements and dietary plans.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle, diet & sleep
Description: The control group will receive lifestyle and dietary advice accompanied by meal replacements and dietary plans. The experimental group will additionally receive a sleep improvement program based on CBTi.
Study: NCT04024618

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Parenteral Nutrition/Enteral Nutrition
Description: Patients randomized to the parenteral nutrition arm will receive nutrition by IV and patients randomized to the enteral nutrition arm will receive nutrition by NG tube.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Parenteral Nutrition/Enteral Nutrition
Description: Patients randomized to the parenteral nutrition arm will receive nutrition by IV and patients randomized to the enteral nutrition arm will receive nutrition by NG tube.
Study: NCT02238262

Intervention type: DRUG
Intervention: Telmisartan
Study: NCT01854099

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PEP-CMV
Description: 500 µg of PEP-CMV vaccine given intradermally on day 6-8 of each monthly TMZ cycle (standard 200 mg/m\^2 x 5 days) with group 1.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PEP-CMV
Description: 500 µg of PEP-CMV vaccine given intradermally on day 22-24 of each monthly TMZ cycle (standard 200 mg/m\^2 x 5 days) with group 2.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PEP-CMV
Description: 500 µg of PEP-CMV vaccine given intradermally on day 22-24 of each monthly TMZ cycle (dose-intensified 100 mg/m\^2 x 21 days) with group 3.
Study: NCT00594854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PN400 (VIMOVO)
Description: PN400 tablet (500 mg delayed-release naproxen/20 mg immediate-release esomeprazole) given by mouth twice daily (bid).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac/Misoprostol
Description: Over-encapsulated ARTHROTEC® 75 (75 mg diclofenac sodium/200 mcg misoprostol) capsules given by mouth bid.
Study: NCT04160546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib 15 MG
Description: Patients will receive ponatinib 15 mg/day for 104 weeks orally. Ponatinib will be self-administered by the patient on a daily schedule.~Acetyl salicylic acid (ASA) (100 mg) will be used such auxiliary medicinal product in order to prevent vascular occlusive events related with ponatinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid 100 MG
Description: Patients will receive acetylsalicylic acid 100 mg/day for 104 weeks orally.
Study: NCT03506958

Intervention type: PROCEDURE
Intervention: Standard trauma care
Description: In both groups, all procedures and management will be done according to the hospital's standard of care.

Intervention type: PROCEDURE
Intervention: Standard trauma care
Description: In both groups, all procedures and management will be done according to the hospital's standard of care.
Study: NCT03996473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY 88-8223)
Description: 55 kBq/kg, intravenous (IV) injection, every 6 weeks for up to 6 administrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY 88-8223)
Description: 55 kBq/kg, intravenous (IV) injection, every 6 weeks for up to 6 administrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY 88-8223)
Description: 55 kBq/kg, intravenous (IV) injection, every 6 weeks for up to 6 administrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg, IV infusion, every 3 weeks for a maximum of up to 35 administrations

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: 200 mg, IV infusion, every 3 weeks for a maximum of up to 35 administrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg, IV infusion, every 3 weeks for a maximum of up to 35 administrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg, IV infusion, every 3 weeks for a maximum of up to 35 administrations
Study: NCT02212704

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular stimulation by use of the turntable (static roll-tilt while the head is roll-tilted relative to the trunk)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D-video-head impulse testing
Description: Evaluation of semicircular canal function. This intervention is part of the screening to determine suitability for this study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular-evoked myogenic potentials (VEMPs)
Description: Evaluation of otolith function. This intervention is part of the screening to determine suitability for this study
Study: NCT03712891

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coffee
Description: Patients will receive coffee in a Styrofoam cup at a temperature of 125 degree Fahrenheit or less. Coffee will be offered to the patient in the PACU once the patient's gag reflex has been restored following their procedure. Volume of estimated coffee consumption will be measured using a sample scale (with a maximum of 300mL of coffee offered)
Study: NCT05784584

Intervention type: PROCEDURE
Intervention: Blood samples collection
Description: The study population will take blood samples for virological and immunological measurements.
Study: NCT03241745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 480 mg IV once every 4 weeks
Study: NCT01381692

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV or SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study: NCT04118660

Intervention type: OTHER
Intervention: Tissue Banking
Description: Blood, tissue, and fluid collection
Study: NCT03364803

Intervention type: OTHER
Intervention: Cushing's QoL (Quality of Life Questionnaire)
Description: Cushing's QoL is a validated disease specific questionnaire consisting of 12 questions on a five-point Likert scale ranging from always to never. The total score ranges from 12 to 60, with a lower score indicating a greater negative impact on health related QoL. This is converted to a 0-100 scale, 0 indicating the worst and 100 indicating the best QoL

Intervention type: OTHER
Intervention: Nottingham Health Profile (NHP)
Description: NHP is used in patients to assess general health and quality of life. This assessment consists of 38 yes/no questions that are subdivided into six scales assessing impairments: pain (eight items), energy level (three items), sleep (five items), emotional reactions (nine items), social isolation (five items) and physical mobility (eight items). A higher score indicates more impairment

Intervention type: OTHER
Intervention: Hospital Anxiety and Depression Scale (HADS)
Description: HADS consists of 14 items pertaining to anxiety and depression, with each item measured on a four-point scale. Total scores for the anxiety and depression subscales range from 0 to 21. A higher score indicates greater symptomatology

Intervention type: OTHER
Intervention: Perceived Stress Scale (PSS)
Description: The PSS predicts both objective biological markers of stress and increased risk of disease in patients with higher stress levels.

Intervention type: OTHER
Intervention: Barratt's Impulsivity Scale (BIS)
Description: BDI and BIS in combination have demonstrated that depression and/or binge eating may be mediating factors for the outcome of obesity

Intervention type: OTHER
Intervention: Beck Depression Inventory (BDI)
Description: BDI and BIS in combination have demonstrated that depression and/or binge eating may be mediating factors for the outcome of obesity
Study: NCT00073788

Intervention type: PROCEDURE
Intervention: PET Scans
Description: PET Scan to look for coronary flow reserve, heart rate variability, and carotid ultrasound measures (mean intermediate thickness of the far fall of the carotid artery).

Intervention type: PROCEDURE
Intervention: PET Scans
Description: PET Scan to look for coronary flow reserve, heart rate variability, and carotid ultrasound measures (mean intermediate thickness of the far fall of the carotid artery).
Study: NCT00249847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine controlled-release
Description: 2-12.5 mg tablets, orally, every day for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen
Description: 0.625 mg tablet, orally, every day for 4 weeks
Study: NCT04288778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin + Metformin hydrochloride (Fixed Dose Combination)
Description: Participants will receive canagliflozin + metformin hydrochloride IR fixed-dose combination, 50 milligram (mg) + 500 mg or 50 mg + 1000 mg, will be provided as tablets for oral administration. The study Treatment duration will be of 24 weeks.
Study: NCT02269033

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigated Latinas
Description: Patient navigators provided culturally sensitive support and guidance to Latina women who presented radiologic abnormalities categorized as BI-RADS 3, 4 and 5. Patient Navigators also collected clinical information from the patients' medical charts.
Study: NCT01698892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I.V Sedation
Description: Patients who will undergo bronchoscopy will be followed during one day. They will be randomized in the I.V. sedation group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sublingual sedation
Description: Patients who will undergo bronchoscopy will be followed during one day. They will be randomized in the sublingual sedation group
Study: NCT00877487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD489 (Lisdexamfetamine dimesylate)
Description: 1 capsule (either 30, 50, or 70mg strength) per day for 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule (identical to drug capsules) per day for 4 weeks during the double blind period.
Study: NCT00819845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carvedilol
Description: carvedilol vs ramipril

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramipril
Description: carvedilol vs ramipril
Study: NCT02269033

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non Navigated Latinas
Description: A convenience sampling approach was used to recruit non navigated Latinas. Eligibility criteria targeted self-identified Latinas at community-based health clinics, aged \> 18 years with an abnormal breast screening mammogram resulting in BI-RADS 3, 4 or 5. Controls were chosen by determining eligibility consecutively backwards from the study start date.
Study: NCT03436433

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lacosamide
Description: LCM 100mg twice a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Description: LEV 1000mg twice a day.
Study: NCT01411176

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Menthol
Description: 20 mL NPO-11 in a prefilled plastic syringe

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is included same additives as active comparator.
Study: NCT01634620

Intervention type: DEVICE
Intervention: NIOX MINO® Instrument (09-1100)
Description: FeNO measurements will be performed according to the Perform FeNO Measurement guidelines on page 7 of the NIOX MINO® User Manual (February, 2011)
Study: NCT01527656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 70
Description: A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-12 days will take place between dosing visits

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 70
Description: A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-12 days will take place between dosing visits
Study: NCT04328129

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Human biological samples
Description: * Blood sample~* Nasopharyngeal swab.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Human biological samples
Description: * Blood sample~* Nasopharyngeal swab.
Study: NCT02659007

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: yoga
Description: 8 weeks of yoga, twice a week. sitting, standing, and floor postures with meditation and breath work
Study: NCT01210846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tivozanib
Description: 1 x 1.5 mg capsule of tivozanib orally once daily for 21 days
Study: NCT02764372

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Serious games
Description: Participants played serious games developed for Kinect in the the EU FP7 STREP Project REHAB@HOME N. 306113

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exergames
Description: Participants played exergames existent in the Wii game console
Study: NCT04263558

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Emotion child
Description: The MFS will include an idiographic measure of personal aims, symptom burden, displayed on a visual data dashboard to guide further intervention. The EMOTION intervention for children 9 to 12 years with symptoms of anxiety and/or depression will be used in a standard/long version (16 sessions) and a short (8 sessions) but optimized version, using a partial web-based solution with virtual reality (VR)-technology for behavioral experiments and exposure (in short and long version). Parental involvement: Parental participation in a 5-session parent group (high involvement) versus sharing information with parents via a brochure (low Parental involvement).
Study: NCT04927559

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study: NCT03364803

Intervention type: OTHER
Intervention: State-Trait Anxiety Inventory (STAI)
Description: The STAI provides data to help distinguish between anxiety and depression.

Intervention type: OTHER
Intervention: State Food Craving Questionnaire-State (FCQ-S)
Description: The FCQ-S consists of 15 items assessing: desire to eat, anticipation of positive reinforcement from eating, anticipation of negative reinforcement (reduction of negative affect) from eating, lack of control over eating, and (physiological) hunger; higher scores reflect stronger food craving. Participants respond, using a Likert-type scale, how much each item is true of them right now.
Study: NCT03568708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Estrogen
Description: In an open-label fashion, participants with POI will receive transdermal estradiol (beginning at a dose of 25 µg/patch applied weekly), with the dose increased at 3, 6 12, and 18 months (to 37.5, 50, 75, and 100 µg/patch).
Study: NCT00940914

Intervention type: DRUG
Group type: OTHER
Intervention: ioflupane 123I (DATSCAN®)
Description: One administration (2,5 ml) of ioflupane 123I 0,07-0,13 µg/ml; 74 MBq/ml; IV (in the vein)

Intervention type: DRUG
Group type: OTHER
Intervention: ioflupane 123I (DATSCAN®)
Description: One administration (2,5 ml) of ioflupane 123I 0,07-0,13 µg/ml; 74 MBq/ml; IV (in the vein)
Study: NCT00555334

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA
Description: radiofrequency ablation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RFA
Description: radiofrequency ablation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamivudine or entecavir
Description: lamivudine (100mg qd) or entecavir (0.5mg qd) after RFA
Study: NCT00511147

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IGIV3I Grifols 10%
Description: IGIV3I Grifols 10% 1 g/kg/day given on two consecutive days, Day 1 and Day 2, for a total dose of 2 g/kg over two days.
Study: NCT03416335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-0509
Description: Each patient treated will receive DSP-0509 at the dose fixed for that Part or cohort administered as a constant rate IV infusion over 10 minutes using a syringe pump.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-0509, Pembrolizumab
Description: Each patient treated will receive DSP-0509 at the dose fixed for that Part or cohort administered as a constant rate IV infusion over 10 minutes using a syringe pump and is given in combination with pembrolizumab which should be administered following the dosing schedule of the approved label (200 mg IV q3w)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-0509, Pembrolizumab
Description: Each patient treated will receive DSP-0509 at the Recommended Phase II Dose (RP2D) level as determined in Part B. It is given as a constant rate IV infusion over 10 minutes using a syringe pump and is given in combination with pembrolizumab which should be administered following the dosing schedule of the approved label (400 mg IV q6w)
Study: NCT04514289

Intervention type: DRUG
Intervention: Indocyanine green solution
Description: Indocyanine green (ICG) is a cyanine dye used in medical diagnostics.ICG is a fluorescent dye that is used in medicine as an indicator substance.

Intervention type: DRUG
Intervention: Indocyanine green solution
Description: Indocyanine green (ICG) is a cyanine dye used in medical diagnostics.ICG is a fluorescent dye that is used in medicine as an indicator substance.
Study: NCT02133066

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bedside Ultrasound-Assisted Site Marking
Description: Patient will receive a bedside ultrasound-assisted site marking of the most appropriate site for lumbar puncture prior to the clinician completing the spinal tap using Mindray M7 Ultrasound.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mindray M7 Ultrasound
Description: Patient will receive a bedside ultrasound exam of the most appropriate site for lumbar puncture prior to the clinician completing the spinal tap

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Routine lumbar puncture
Description: Lumbar puncture will be performed per routine standard of care
Study: NCT03238326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Once daily, oral tablets
Study: NCT01037829

Intervention type: OTHER
Intervention: Non-intervention observational study
Description: Non-intervention observational study
Study: NCT04245748

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram, a SSRI, commercially known as LexaproTM, is commonly prescribed for anxiety disorders and is FDA-approved for acute and maintenance treatment of MDD and GAD.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Duloxetine, a SNRI, commercially known as CymbaltaTM, is FDA-approved for the treatment of GAD, MDD, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain in adults.
Study: NCT01149499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: 1000 mg Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir
Description: 1000 mg Tablet
Study: NCT02484456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV 101 (4-Chlorokynurenine)
Description: L-4-chlorokynurenine (4-Cl-KYN) was developed as a prodrug that is rapidly converted in vivo to its active metabolite 7-chlorokynurenic acid (7-Cl-KYNA), a well-characterized N-Methyl-D-aspartate receptor (NMDAR) antagonist at the glycine site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV 101 (4-Chlorokynurenine)
Description: L-4-chlorokynurenine (4-Cl-KYN) was developed as a prodrug that is rapidly converted in vivo to its active metabolite 7-chlorokynurenic acid (7-Cl-KYNA), a well-characterized N-Methyl-D-aspartate receptor (NMDAR) antagonist at the glycine site.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Comparator
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Comparator
Description: Placebo